Filing Flows › Vertex Pharmaceuticals (VRTX) › Stock forecast & fair value
Vertex Pharmaceuticals (VRTX) stock forecast and fair value
Vertex Pharmaceuticals (VRTX) trades at $547.09. 28 analysts' median price target is $600.00 (+10%), from $350.00 to $725.00. Across 26 valuation methods the middle fair value is $311.29 (-43%); the DCF says $314.43.
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| Regime-switching Monte Carlo 10th–90th | $142.66 | $387.08 | $816.41 | -29% |
| DCF — Monte Carlo 10th–90th percentile | $179.77 | $314.43 | $475.92 | -43% |
| P/E vs peers | $203.60 | $279.74 | $672.95 | -49% |
| P/E vs peers, weighted | $269.67 | $504.74 | $761.65 | -8% |
| P/E vs peers, matched | $319.42 | $362.95 | $487.92 | -34% |
| EV/EBITDA vs peers | $162.22 | $298.38 | $369.72 | -45% |
| EV/EBITDA vs peers, weighted | $298.38 | $355.43 | $360.93 | -35% |
| EV/EBITDA vs peers, matched | $298.63 | $306.01 | $331.29 | -44% |
| EV/Sales vs peers | $122.87 | $205.42 | $390.49 | -62% |
| EV/Sales vs peers, weighted | $169.28 | $281.12 | $406.09 | -49% |
Vertex Pharmaceuticals' latest quarter
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for VRTX stock?
The median of 28 analysts' 12-month targets is $600.00, +10% from $547.09; the range is $350.00 to $725.00. The average rating is buy.
What is Vertex Pharmaceuticals' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $119.44 and $592.36, with a middle value of $311.29 against a price of $547.09. Each method's assumptions are on the page.
Does Vertex Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is VRTX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.